| 100431-6 | Cells.CD3+CD14-CD45+.LRBA mean fluorescence intensity (Blood, flow cytometry (fc)) |
| 100433-2 | Cells.CD3-CD14-CD19+CD45+.LRBA mean fluorescence intensity (Blood, flow cytometry (fc)) |
| 112424-7 | t(10;19)(10p11.21;19p13.3)(CUL2,KDM4B) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 18112-3 | Aortic valve Regurgitation degree (qualitative, us.doppler) |
| 18113-1 | Mitral valve Regurgitation degree (qualitative, us.doppler) |
| 18114-9 | Pulmonic valve Regurgitation degree (qualitative, us.doppler) |
| 18115-6 | Tricuspid valve Regurgitation degree (qualitative, us.doppler) |
| 18178-4 | Left ventricular Wall motion index (qualitative, us) |
| 18649-4 | Psychiatric rehabilitation treatment plan, Signature of responsible attending physician on file (qualitative) |
| 18650-2 | Psychiatric rehabilitation treatment plan, Signature of responsible rehabilitation professional on file (qualitative) |
| 18840-9 | Left ventricular Wall motion index (us narrative) |
| 19148-6 | RhoGam candidate (yes/no) (qualitative) |
| 19150-2 | Specimen creatinine acceptable (Urine, qualitative) |
| 19152-8 | Specimen specific gravity acceptable (Urine, qualitative) |
| 19816-8 | Images taken Endoscopy procedure (qualitative) |
| 19826-7 | Informed consent obtained (qualitative) |
| 21095-5 | BCL2 gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21551-7 | t(15;17)(q24.1;q21.1)(PML,RARA) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21614-3 | CDKN2A gene deletion or Tissue (Blood, qualitative, molecular genetics method) |
| 21615-0 | CDKN2B gene deletion or Tissue (Blood, qualitative, molecular genetics method) |
| 21620-0 | STS gene deletion or Tissue (Blood, qualitative, molecular genetics method) |
| 21647-3 | CBS gene p.G307S or Tissue (Blood, qualitative, molecular genetics method) |
| 21648-1 | CBS gene p.I278T or Tissue (Blood, qualitative, molecular genetics method) |
| 21706-7 | MT-ND4 gene p.R304H or Tissue (Blood, qualitative, molecular genetics method) |
| 21708-3 | MT-ATP6 gene p.L156R or Tissue (Blood, qualitative, molecular genetics method) |
| 21744-8 | CCND1 gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21745-5 | BCL2 gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21746-3 | BCL6 gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21747-1 | HC gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21748-9 | Kappa LC gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21749-7 | Lambda LC gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21750-5 | MYC gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21751-3 | TCRB gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21752-1 | TCRD gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21753-9 | TCRG gene rearrangements or Tissue (Blood, qualitative, molecular genetics method) |
| 21761-2 | FRAXE gene CGG repeats or Tissue (Blood, qualitative, molecular genetics method) |
| 21770-3 | Chromosome 12 trisomy or Tissue (Blood, qualitative, cytogenetics) |
| 21771-1 | Chromosome 21 trisomy or Tissue (Blood, qualitative, cytogenetics) |
| 21772-9 | Chromosome 7 trisomy or Tissue (Blood, qualitative, cytogenetics) |
| 21773-7 | Chromosome 8 trisomy or Tissue (Blood, qualitative, cytogenetics) |
| 21774-5 | Chromosome 9 trisomy or Tissue (Blood, qualitative, cytogenetics) |
| 21799-2 | t(1;13)(p36.13;q14.1)(PAX7,FOXO1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21800-8 | t(1;19)(q23.3;p13.3)(PBX1,TCF3) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21801-6 | t(11;14)(q13;q32)(CCND1,IGH) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21802-4 | t(11;19)(q23;p13.3)(MLL,MLLT1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21803-2 | t(11;22)(q24;q12.2)(FLI1,EWSR1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21804-0 | t(11;22)(p13;q12.2)(WT1,EWSR1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21805-7 | t(12;16)(q13;p11.2)(DDIT3,FUS) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21806-5 | t(12;21)(p13;q22.3)(ETV6,RUNX1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21807-3 | t(12;22)(q13;q12.2)(ATF1,EWSR1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21808-1 | t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21809-9 | t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript major break points or Tissue (Blood, qualitative, molecular genetics method) |
| 21810-7 | t(14;18)(q32;q21.3)(IGH,BCL2) fusion transcript minor break points or Tissue (Blood, qualitative, molecular genetics method) |
| 21811-5 | t(15,17)(PML,RARA) Translocation or Tissue (Blood, qualitative, molecular genetics method) |
| 21812-3 | t(2;13)(q36.1;q14.4)(PAX3,FOXO1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21813-1 | t(2;5)(p23;q35.1)(ALK,NPM1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21814-9 | t(21;22)(q22.3;q12.2)(ERG,EWSR1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21815-6 | t(4;11)(q21.3;q23)(AFF1,MLL) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21816-4 | t(5;12)(q33.1;p13)(PDGFRB,ETV6) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21817-2 | t(6;9)(p22;q34)(DEK,NUP214) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21818-0 | t(8;14)(q24;q32)(MYC,IGH) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21819-8 | t(8;21)(q22;q22.3)(RUNX1T1,RUNX1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21820-6 | t(9;11)(p22;q23)(MLLT3,MLL) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21821-4 | t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21822-2 | t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript major break points or Tissue (Blood, qualitative, molecular genetics method) |
| 21823-0 | t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript minor break points or Tissue (Blood, qualitative, molecular genetics method) |
| 21824-8 | t(9;22)(q22;q12.2)(NR4A3,EWSR1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21825-5 | t(X;18)(q11.2;p11.23)(SS18,SSX1) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21826-3 | t(X;18)(q11.2;p11.22)(SS18,SSX2) fusion transcript or Tissue (Blood, qualitative, molecular genetics method) |
| 21853-7 | Sequence number central.patient Cancer (qualitative) |
| 21867-7 | Sequence number.hospital Cancer (qualitative) |
| 21956-8 | Referred to support services Cancer (qualitative) |
| 21991-5 | Age and Site and Morphology override flag Cancer case (qualitative) |
| 21992-3 | Sequence numberanddiagnosis confirm override flag Cancer case (qualitative) |
| 21993-1 | Site and laterality and sequence number override flag Cancer case (qualitative) |
| 21994-9 | Surgery and diagnosis confirm override flag Cancer case (qualitative) |
| 21995-6 | Siteandtype override flag Cancer case (qualitative) |
| 21996-4 | Histology override flag Cancer case (qualitative) |
| 21997-2 | Report source override flag Cancer case (qualitative) |
| 21998-0 | Ill defined site override flag Cancer case (qualitative) |
| 21999-8 | Leukemia and lymphoma override flag Cancer case (qualitative) |
| 22000-4 | Site and behavior override flag Cancer case (qualitative) |
| 22001-2 | Site and extent of disease and diagnosis date override flag Cancer case (qualitative) |
| 22002-0 | Site and laterality and extent of disease override flag Cancer case (qualitative) |
| 22003-8 | Site and laterality and morphology override flag Cancer case (qualitative) |
| 22016-0 | SEER record number Cancer case (qualitative) |
| 27495-1 | Alcohol-substance abuse rehabilitation treatment plan, Signature of responsible attending physician on file (qualitative) |
| 27496-9 | Alcohol-substance abuse rehabilitation treatment plan, Signature of responsible rehabilitation professional on file (qualitative) |
| 27543-8 | Cardiac rehabilitation treatment plan, Signature of responsible attending physician on file (qualitative) |
| 27544-6 | Cardiac rehabilitation treatment plan, Signature of responsible rehabilitation professional on file (qualitative) |
| 27565-1 | Skilled nursing treatment plan, Signature of responsible attending physician on file (qualitative) |
| 27566-9 | Skilled nursing treatment plan, Signature of responsible rehabilitation professional on file (qualitative) |
| 27616-2 | Occupational therapy treatment plan, Signature of responsible attending physician on file (qualitative) |
| 27617-0 | Occupational therapy treatment plan, Signature of responsible rehabilitation professional on file (qualitative) |
| 27679-0 | Physical therapy treatment plan, Signature of responsible attending physician on file (qualitative) |
| 27680-8 | Physical therapy treatment plan, Signature of responsible rehabilitation professional on file (qualitative) |
| 27718-6 | Respiratory therapy treatment plan, Signature of responsible attending physician on file (qualitative) |
| 27719-4 | Respiratory therapy treatment plan, Signature of responsible rehabilitation professional on file (qualitative) |
| 27769-9 | Medical social services treatment plan, Signature of responsible attending physician on file (qualitative) |
| 27770-7 | Medical social services treatment plan, Signature of responsible rehabilitation professional on file (qualitative) |